September 2019
The Oncology Pharmacist's Blind Spot
September 17, 2019
Article
The Educated Patient
Hematology and oncology pharmacists discussed patient outreach at a panel during the Hematology/Oncology Pharmacy Association’s (HOPA) annual conference in April.
Medical Marijuana in Community Oncology
September 17, 2019
Article
Features
During a presentation at the recent Community Oncology Alliance Annual Conference in Orlando, Florida, Ray Bailey, RPh, discussed the implications of medical marijuana for patients with cancer.
Lessons Learned: Starting a Health-System, Oncology-focused Specialty Pharmacy
September 17, 2019
Article
Features
Health-system–owned and operated specialty pharmacies have become a trend to not only capture previously unrealized profit but to also close the gap between provider, patient, and medication.
The Oncology Drug Pathway: Getting Medications From the Pharmacy to the Patient
September 17, 2019
Article
Features
Despite advances in cancer care, patients typically face obstacles to treatment.
The Importance of Financial Counseling Services for Patients With Cancer
September 17, 2019
Article
Features
As the cost of treating the disease has risen, so too have the direct medical care expenses that patients pay out of pocket, as commercial insurers increasingly shift the burden of paying for treatment to patients through higher premiums, deductibles, and co-pays.
The Community Oncology Pharmacy Association: Meeting the Needs of Oncology Pharmacies
September 12, 2019
Article
Features
As a nonprofit focused on enhancing patient care. COPA is in a unique position to serve as a noncommercial organization dedicated to addressing community oncology pharmacy issues, all in the sole interest of patient care.
Complementary Therapies and Patients With Cancer: Pearls for Avoiding Adverse Events
September 10, 2019
Article
Clinical Insights
Complementary therapies, such as supplements or aromatherapy, have the potential to benefit patients with cancer, but can also trigger adverse events when they interact with oncology medications.
Combating Advancing Cancers With CAR T-Cell Therapy
September 08, 2019
Article
Innovations
Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.
Expanding Patient Channels to Oncology Products
September 06, 2019
Article
Editor
As new specialty products have begun to dominate the developmental pipeline, specialty pharmacy has entered the mainstream of the supply chain to the point where we can arguably refer to much of the channel as “traditional specialty.”
DAURISMO for Acute Myeloid Leukemia
September 05, 2019
Article
Clinical Insights
On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.
ERLEADA for Prostate Cancer
September 04, 2019
Article
Clinical Insights
On February 14, 2018, the FDA approved apalutamide (Erleada) by Janssen Biotech Inc for the treatment of nonmetastatic castration-resistant prostate cancer (NM-CRPC).